NASDAQ: ACRS | Healthcare / Biotechnology / USA |
6.41 | -0.1300 | -1.99%![]() | Vol 354 402 | 1Y Perf -67.99% |
Feb 21st, 2019 16:00 |
BID | 6.41 | ASK | 6.42 | ||
Open | 6.51 | Previous Close | 6.54 | ||
Pre-Market | - | After-Trading | 6.41 | ||
- -% | - -% |
Target Price | 39.50 | Analyst Rating | Strong Buy 1.00 | |
Potencial % | 516.23 | Finscreener Ranking | — - | |
Insiders Trans % 3/6/12M | -/100/38 | Value Ranking | — - | |
Insiders Value % 3/6/12M | -/100/90 | Growth Ranking | — - | |
Insiders Shares Cnt. % 3/6/12M | -/100/94 | Income Ranking | — - | |
Market Cap (mil) | 262 | Earnings Rating | — | |
Price Range Ratio 52wk % | 2.79 | Earnings Date | 11th Mar 2019 |
Today's Price Range 6.326.65 | 52wk Range 5.9522.41 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Month | 4.23% | ||
3 Months | -25.12% | ||
6 Months | -58.70% | ||
1 Year | -67.99% | ||
3 Years | -61.75% | ||
5 Years | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Quick Ratio | 6.10 | |||
Current Ratio | 6.50 | |||
Long Term Debt to Total Capital | - | |||
Total Debt to Equity | 0.00 | |||
Interest Coverage | - | |||
Leverage Ratio | 1.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Gross Margin | 44.80 | |||
EBIT Margin | -1 641.50 | |||
EBITDA Margin | -1 626.70 | |||
Pre-tax Profit Margin | - | |||
Profit Margin | - |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
PE Ratio | - | |||
PB Ratio | 2.01 | |||
PS Ratios | 56.17 | |||
Price to Cash Flow | - | |||
Price to Free Cash Flow | -3.90 | |||
Cash Flow Per Share | -2.97 | |||
Price to Tangible Book | 2.44 | |||
Book Value per Share | 3.57 | |||
Enterprise Value (in ths.) | 159 832 |
Management Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Return on Equity (5Y Avg) | -33.62 | |||
ROE last 12 Months | -60.36 | |||
Return on Assets (5Y Avg) | -14.74 | |||
ROA last 12 Months | -53.86 | |||
Return on Capital (5Y Avg) | - | |||
ROC last 12 Months | -59.79 | |||
Return on invested Capital Q | -20.36 | |||
Return on invested Capital Y | -34.69 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 7.20 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Revenue LTM (in ths.) | 5 422 | |||
Revenue per Share | 0.13 | |||
Revenue Growth 3 Years | - | |||
Revenue Growth 5 Years | - |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Dividend Yield | - | |||
Dividend Rate | - | |||
Dividend Growth 3 Years | - | |||
Dividend Growth 5 Years | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2018 | -1.25 | -1.06 | 15.20 |
Q02 2018 | -0.95 | -1.01 | -6.32 |
Q01 2018 | -0.99 | -0.98 | 1.01 |
Q04 2017 | -0.90 | -0.80 | 11.11 |
Q03 2017 | -0.86 | -0.63 | 26.74 |
Q02 2017 | -0.68 | -0.56 | 17.65 |
Q01 2017 | -0.54 | -0.48 | 11.11 |
Q04 2016 | -0.59 | -0.49 | 16.95 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2018 QR | -0.96 | -1.05 | Negative |
12/2018 QR | -1.27 | -7.63 | Negative |
12/2018 FY | -4.01 | -0.25 | Negative |
12/2019 FY | -3.66 | -3.39 | Negative |
Next Report Date | 11th Mar 2019 |
Estimated EPS Next Report | -0.96 |
Estimates Count | 2 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 354 402 |
Shares Outstanding (in ths.) | 40 936 |
Trades Count | 1 859 |
Dollar Volume | 1 967 628 |
Avg. Volume | 443 662 |
Avg. Weekly Volume | 450 711 |
Avg. Monthly Volume | 414 178 |
Avg. Quarterly Volume | 579 374 |
Week | Month | Three Months | Six Months |
---|---|---|---|
Bearish Bullish 0%100% | Bearish Bullish 43%57% | Bearish Bullish 61%39% | Bearish Bullish 63%37% |
There are no comments yet.
![]() | ![]() | ![]() | ![]() | ![]() | ![]() |